(I-Newswire) March 21, 2010 - WORCESTER -- Advanced Cell Technology, Inc. (OTCBB: ACTC), a biotechnology company applying cellular technology in the field of regenerative medicine, announced that company Chairman and Chief Executive Officer William M. Caldwell IV was interviewed yesterday on Bloomberg Radio's popular mid-day program, The Hays Advantage, hosted by Kathleen Hays.
The discussion covered Advanced Cell’s retinal pigment epithelium (RPE) cell program for the treatment of Stargardt's disease and age-related macular degeneration (AMD), which is the leading cause of blindness in Americans over 60 years of age. Mr. Caldwell and Mr. Hays discussed the size of the potential market for an embryonic stem cell-based cure for AMD, with Mr. Caldwell commenting, "Kathleen, if you and I live long enough, we most likely will get [AMD]. Over ten million Americans suffer from this disease."
Mr. Caldwell was Ms. Hays' sole guest for the wide-ranging, 20-minute interview. Other topics included health care reform, the importance of government funding of basic science research and development, and the investment potential of Advanced Cell Technology and other companies working in the regenerative medicine field.
Ms. Hays concluded the discussion of AMD and the potential for ACTC’s RPE therapy to address the disease with a positive assessment: "It seems that, as a society, we might come out ahead, investing all the money in companies like yours, paying for these treatments, if [the result is that people suffering from AMD] can still see when they get old."
Mr. Caldwell also discussed some of Advanced Cell Technology's other research programs, including its research into producing blood from embryonic stem cells, saying, "We can manufacture blood, and hopefully that will have all sorts of applications, including for the military… to address issues around the lack of blood for soldiers out in the field." He also discussed the company's Myoblast program for the treatment of heart failure.
Mr. Caldwell commented on the overall stem cell industry, saying, "It's an exciting field and it needs a little bit of a kick-start. That's why we believe our initial indication will help validate the industry, because it's what we believe to be low-hanging fruit."
The interview may be accessed on ACT's website at the following link:
http://www.advancedcell.com/media-gallery-item/bloomberg-radio-interviews-actc-chairman-and-ceo-william-m-caldwell-iv
The Company also announced that it would present today at BIO- Europe Spring 2010 4th Annual International Partnering Conference, an event that brings many of the leading international biotechnology companies to Barcelona, Spain.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2009. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact:
Press:
Bill Douglass
Gotham Communications, LLC
(646) 450-3615
Investors:
CEOcast, Inc. for Advanced Cell
Dan Schustack, 212-732-4300
About Advanced Cell Technology, Inc.:
A.C.T. Holdings, Inc., a Nevada corporation, and its wholly-owned subsidiary, Advanced Cell Technology, Inc., a Delaware corporation, is a leading biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company is currently headquartered in Worcester, Massachusetts.
Company Contact Information
Advanced Cell Technology, Inc.
Nicholas Wade
P.O. Box 1700
90406
Phone : (310) 576 0611
|
